Who Generates Higher Gross Profit? Gilead Sciences, Inc. or Alkermes plc

A Tale of Two Biotech Giants: Gilead Sciences vs. Alkermes

In the competitive world of biotechnology, Gilead Sciences, Inc. and Alkermes plc stand out as key players. Over the past decade, Gilead has consistently outperformed Alkermes in terms of gross profit. From 2014 to 2023, Gilead's gross profit averaged around $21.6 billion annually, dwarfing Alkermes' average of approximately $519 million. This stark contrast highlights Gilead's dominant market position, generating nearly 40 times more profit than Alkermes.

However, Alkermes has shown impressive growth, with its gross profit increasing by over 700% from 2014 to 2023. In 2023, Alkermes reached a milestone, generating $1.41 billion in gross profit, a significant leap from its 2014 figures. This growth trajectory suggests a promising future for Alkermes as it continues to innovate and expand its market presence.

The data underscores the dynamic nature of the biotech industry, where innovation and strategic positioning can lead to substantial financial gains.